← board
OPTEY
Opthea Limiteddistress 4/10 · elevated risk$0.03+21%today-99% from 52w high
Ophthalmology 2
Lead: Neovascular Age-related Macular Degeneration · est. market ~$12B (approx, global)
Revenue
pre-revenue
Liquidity
$48M
Runway
0.3 yrs
Shares 1y
—
Price & events
+347.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+21.4%
1D
+0.0%
1W
+69.2%
1M
-43.2%
3M
+347.4%
6M
-99.0%
1Y
-98.4%
2Y
-99.5%
5Y
-99.7%
All
Overview
- Volume
- 700
- 52 Week Range
- $0.01 – $3.41
- Float Shares
- 143.80M
- Short %
- 0.42%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 3.46%
- RVOL
- 0.04x
- Beta
- 1.53
Pipeline stages · 1 programs
2.0 mg OPT-302, 0.5 mg ranibizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-03-31 | Phase 3 | 2.0 mg OPT-302, 0.5 mg ranibizumab | Neovascular Age-related Macular Degeneration | 986 | terminated |
| 2025-03-31 | Phase 3 | 2.0 mg OPT-302, 2.0 aflibercept | Neovascular Age-related Macular Degeneration | 998 | terminated |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- 2024-07-03SC 13G/Astrategic_stake
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Neovascular Age-related Macular Degeneration
Recent news
- 2026-07-07OPTEY SEC Filings - Ceryvyn Therapeutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
- 2026-07-07Regal Partners reports 45.2M shares in Opthea (CKDXF) - Stock Titan
- 2026-07-03Opthea Ltd has Changed its Name to Ceryvyn Therapeutics Limited - marketscreener.com
- 2026-06-04Why IperionX, Northern Star, Opthea, and Superloop shares are tumbling today - The Motley Fool Australia
- 2026-06-03Why Catapult Sports, Harvey Norman, Inghams, and Opthea shares are sinking today - The Motley Fool Australia
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.